COST-EFFECTIVENESS OF RIVAROXABAN FOR THE TREATMENT OF PULMONARY EMBOLISM IN CANADA

被引：1
|
作者：
Levac, B. [1 ]
Marrie, J. [1 ]
Chin, W. [2 ]
Hassan, F. [3 ]
Bamber, L. [4 ]
McLeod, E. J. [3 ]
机构：
[1] Bayer Inc, Toronto, ON, Canada
[2] ILEX Consulting Inc, Toronto, ON, Canada
[3] IMS Hlth, London, England
[4] Bayer Healthcare, Leverkusen, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.684
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV90
引用
收藏
页码：A117 / A118
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
    Heisen, Marieke
    Treur, Maarten J.
    Heemstra, Harald E.
    Giesen, Eric B. W.
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 813 - 824
  • [42] Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China
    Dong, Shu-Jie
    Wu, Bin
    Zhai, Suo-Di
    Zhang, Yan-Jun
    Chu, Yun-Bo
    Gupta, Parul
    Li, Ya-Huei
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 144 - 156
  • [43] Cost-Effectiveness Of Prognostic Strategies In Non-High Risk Pulmonary Embolism
    Celis, C. A.
    Londono, D.
    Marin, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [44] Comparison of Guidelines for Evaluation of Suspected Pulmonary Embolism in Pregnancy A Cost-effectiveness Analysis
    McCandlish, John Austin
    Feizullayeva, Chinara
    Spyropoulos, Alex C.
    Cronin, Paul P.
    Naidich, Jason J.
    Brenner, Benjamin
    McGinn, Thomas
    Sanelli, Pina C.
    Cohen, Stuart L.
    CHEST, 2022, 161 (06) : 1628 - 1641
  • [45] Spiral CT angiography for suspected pulmonary embolism: A cost-effectiveness analysis - Response
    van Erkel, AR
    Pattynama, PMT
    ACADEMIC RADIOLOGY, 1999, 6 (01) : 74 - 75
  • [46] COST-EFFECTIVENESS ANALYSIS OF VARIOUS STRATEGIES IN THE DIAGNOSTIC MANAGEMENT OF PULMONARY-EMBOLISM
    OUDKERK, M
    VANBEEK, EJR
    VANPUTTEN, WLJ
    BULLER, HR
    ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (08) : 947 - 954
  • [47] Cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in Canada
    Haiderali, AM
    Villa, K
    Schrammel, P
    HEPATOLOGY, 1999, 30 (04) : 347A - 347A
  • [48] Cost-effectiveness of asenapine in the treatment of schizophrenia and bipolar disorder in Canada
    Lachaine, J.
    Beauchemin, C.
    Mathurin, K.
    Gilbert, D.
    Beillat, M.
    Corson, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 122 - 122
  • [49] The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada
    Duong, M.
    Wright, E.
    Yin, L.
    Martin-Nunez, I.
    Ghatage, P.
    Fung-Kee-Fung, M.
    CURRENT ONCOLOGY, 2016, 23 (05) : E461 - E467
  • [50] The cost-effectiveness of infliximab (Remicade®) in the treatment of ankylosing spondylitis in Canada
    Kobelt, G
    Andlin-Sobocki, P
    Maksymowych, WP
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (04) : 732 - 740
12345